BBK Adds Global Alliances and Restructures Offerings to Advance Patient Recruitment.
BOSTON-BBK Healthcare, Inc., a leading patient recruitment company for the clinical R&D segment of the pharmaceutical, biotechnology, and medical device industries announces the evolution of its global capabilities and presence to become BBK Worldwide. The company is leveraging its 20-year industry experience in patient recruitment planning and implementation in North America with wider global coverage and a strategic restructuring of offerings to respond to the increasingly complex needs of clinical research sponsors entering new and emerging global markets.
BBK Worldwide's official launch coincides with the Drug Information Association (DIA) Annual Meeting in Philadelphia from June 18–22, where BBK will convene global alliance members for an inaugural summit meeting prior to the DIA conference.
Geographic expansion includes BBK Worldwide offices in London and Prague, and the addition of the BBK Worldwide Alliance, a network of select, best-in-class companies with capabilities in more than 75 countries.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.